Literature DB >> 18237803

Long-term results of salvage radiotherapy for the treatment of recurrent cervical carcinoma after prior surgery.

Cornelis J A Haasbeek1, Apollonia L J Uitterhoeve, Jacobus van der Velden, Dionisio González González, Lukas J A Stalpers.   

Abstract

BACKGROUND AND
PURPOSE: Tumor recurrence after surgery for cervical carcinoma is associated with high fatality and morbidity, forming a major therapeutic challenge. This paper presents our experience with treatment of this patient group by salvage radiotherapy with curative intent.
MATERIALS AND METHODS: Thirty-five patients with a pelvic recurrence after hysterectomy received high-dose radiotherapy. A retrospective analysis of long-term outcome and prognostic factors was performed.
RESULTS: After a median follow-up period of 12.1 years, actuarial 2-,5- and 10-year overall survival rates were 66%, 43% and 33%; disease-free survival rates were 62%, 45% and 41%, respectively. Pelvic control rates at 2-,5- and 10-years were 77%, 69% and 62%. Unfavorable prognostic factors on univariate analysis for survival were: recurrence extending to the pelvic wall versus central recurrence, early recurrence after surgery, external boost versus brachytherapy boost, low total dose and high age. Only a brachytherapy boost and a long interval between surgery and recurrence were significant on multivariate analysis. Severe complications (> or = grade 3) were seen in 6 patients (17%; actuarial after 5 years, 21%).
CONCLUSIONS: Salvage radiotherapy for recurrent cervical carcinoma following surgery may result in 40-50% long-term disease-free survival and an acceptable risk of severe treatment complications, even in patient with recurrences extending to the pelvic wall.

Entities:  

Mesh:

Year:  2008        PMID: 18237803     DOI: 10.1016/j.radonc.2008.01.004

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

1.  Salvage radiotherapy with or without concurrent chemotherapy for pelvic recurrence after hysterectomy alone for early-stage uterine cervical cancer.

Authors:  Sang-Won Kim; Mison Chun; Hee-Sug Ryu; Suk-Joon Chang; Tae Wook Kong; Eun Ju Lee; Yong Hee Lee; Young-Taek Oh
Journal:  Strahlenther Onkol       Date:  2017-03-29       Impact factor: 3.621

2.  Novel substituted (Z)-5-((N-benzyl-1H-indol-3-yl)methylene)imidazolidine-2,4-diones and 5-((N-benzyl-1H-indol-3-yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-triones as potent radio-sensitizing agents.

Authors:  Y Thirupathi Reddy; Konjeti R Sekhar; Nidhish Sasi; P Narsimha Reddy; Michael L Freeman; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2009-11-22       Impact factor: 2.823

3.  Survival and Control Prognosticators of Recurrent Gynecological Malignancies of the Pelvis and Para-aortic Region Treated with Stereotactic Body Radiation Therapy.

Authors:  Shaakir Hasan; Anthony Ricco; Kaylette Jenkins; Rachelle Lanciano; Alexandra Hanlon; John Lamond; Jun Yang; Jing Feng; Michael Good; Joel Noumoff; Luther Brady
Journal:  Front Oncol       Date:  2016-11-22       Impact factor: 6.244

4.  Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.

Authors:  Myong Cheol Lim; Maria Lee; Seung Hyuk Shim; Eun Ji Nam; Jung Yun Lee; Hyun Jung Kim; Yoo Young Lee; Kwang Beom Lee; Jeong Yeol Park; Yun Hwan Kim; Kyung Do Ki; Yong Jung Song; Hyun Hoon Chung; Sunghoon Kim; Jeong Won Lee; Jae Weon Kim; Duk Soo Bae; Jong Min Lee
Journal:  J Gynecol Oncol       Date:  2017-03-15       Impact factor: 4.401

5.  MR-guided SBRT boost for patients with locally advanced or recurrent gynecological cancers ineligible for brachytherapy: feasibility and early clinical experience.

Authors:  Indrawati Hadi; Chukwuka Eze; Stephan Schönecker; Rieke von Bestenbostel; Paul Rogowski; Lukas Nierer; Raphael Bodensohn; Michael Reiner; Guillaume Landry; Claus Belka; Maximilian Niyazi; Stefanie Corradini
Journal:  Radiat Oncol       Date:  2022-01-15       Impact factor: 3.481

6.  Radiotherapy for Vaginal Recurrences of Cervical Cancer in Patients After Prior Surgery: Analysis of Effect and Prognostic Factors.

Authors:  Junfang Yan; Ziye Zheng; Jiawei Zhu; Ke Hu; Xiaorong Hou; Jie Shen; Xin Lian; Shuai Sun; Zheng Miao; Jing Shen; Hui Guan; Qingyu Meng; Fuquan Zhang
Journal:  Front Oncol       Date:  2021-09-13       Impact factor: 6.244

7.  Intraoperative Electron Beam Radiotherapy (IOERT) in the management of locally advanced or recurrent cervical cancer.

Authors:  Brandon M Barney; Ivy A Petersen; Sean C Dowdy; Jamie N Bakkum-Gamez; Kristi A Klein; Michael G Haddock
Journal:  Radiat Oncol       Date:  2013-04-08       Impact factor: 3.481

8.  Chemoradiation and the Role of Adjuvant Chemotherapy in Lymph Nodal-Metastatic Cervical Cancer.

Authors:  Nasir Ali; Azmina Tajdin Valimohammad; Ahmed Nadeem Abbasi; Muhammad Atif Mansha; Asim Hafiz; Bilal Mazhar Qureshi
Journal:  J Glob Oncol       Date:  2017-06-12

9.  Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer.

Authors:  Sushmita B Gordhandas; Beryl Manning-Geist; Christina Henson; Gopa Iyer; Ginger J Gardner; Yukio Sonoda; Kathleen N Moore; Carol Aghajanian; M Herman Chui; Rachel N Grisham
Journal:  Sci Rep       Date:  2022-01-19       Impact factor: 4.379

10.  Surgery followed by concurrent radiochemotherapy as treatment for patients with locally recurrent cervical cancer.

Authors:  Xiang Zhang; Zhongbo Chen; Jianhong Chen; Junjian Wang; Yingchang Wang; Jianqing Zhu
Journal:  Transl Cancer Res       Date:  2021-10       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.